Patrick Malone had what he calls his 'oh, shit' moment in 2024. Malone, a physician turned investor and managing partner at KdT Ventures, was at JPMorgan's annual healthcare conference in San Francisco when a new report stopped him cold.
The chart he saw was going vertical.
In 2022, 23 percent of global pharmaceutical deals over $50 million involved Chinese companies — up from almost nothing just years before. By 2024, that figure had risen to 44 percent. 'The way in which China has captured a remarkable share of global biopharma development at a pace without precedent,' Malone said. 'The slope of that change is so steep, it's very easy to extrapolate where this goes.'
Tim Opler, who specializes in healthcare stocks at the investment bank Stifel Institutional, reached a parallel conclusion earlier this year. An investor asked him a simple question: what percentage of pharmaceutical deals were being done with Chinese companies? When Opler ran the numbers, he found that in 2025, almost 70 percent of the dollars spent on global pharma deals — $137.7 billion — were with start-ups based in China. 'I guess that was the first moment when we realized, 'Oh, China could be a problem,'' he said.
The conventional wisdom holds that China makes cheap, copycat drugs. That picture is out of date. What the data now shows is something categorically different: Chinese biotech start-ups are becoming the primary source of new drug candidates that the world's largest pharmaceutical companies are licensing and developing. The big global firms, which once avoided Chinese-origin compounds, are now racing toward them.
The pattern is familiar. Sector by sector — solar panels, electric vehicles, semiconductors, steel — China has moved from imitation to dominance with a speed that Western competitors consistently underestimated until the moment of reckoning arrived. The pharmaceutical industry, which touches every person on earth, appears to be following the same arc.
The mechanism is not mysterious. State-directed capital, subsidized research infrastructure, and a willingness to absorb losses over long time horizons give Chinese biotech firms structural advantages that private Western investors, answerable to quarterly returns, cannot easily match. Follow the incentive, not the press release.
What is at stake here is not an abstraction. Drug supply chains, intellectual property, and the pricing power over life-saving therapies are all downstream consequences of who controls early-stage pharmaceutical development. The United States learned this lesson painfully with generic drug manufacturing, much of which migrated to China and India over the past two decades. The question now is whether the same dynamic is playing out one level up the value chain — at the level of discovery itself.
The record is public. The numbers are not in dispute. What remains to be seen is whether Washington, and the broader Western pharmaceutical ecosystem, will treat this as the strategic inflection point the data suggests it is — or whether, as has happened before, the response will arrive a decade too late.
